A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-hodgkin Lymphoma

Michael Robertson, Justin Kline, Herbert Struemper, Kevin M. Koch, John W. Bauman, Olivia S. Gardner, Sharon C. Murray, Fiona Germaschewski, Jill Weisenbach, Zdenka Jonak, John F. Toso

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical models. Rituximab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. A phase I study of recombinant human (rh) IL-18 given with rituximab was performed in patients with CD20 lymphoma. Cohorts of 3-4 patients were given infusions of rituximab (375 mg/m) weekly for 4 weeks with escalating doses of rhIL-18 as a 2-hour intravenous infusion weekly for 12 consecutive weeks. Toxicities were graded using standard criteria. Blood samples were obtained for safety, pharmacokinetic, and pharmacodynamic studies. Nineteen patients with CD20 B-cell non-Hodgkin lymphoma were given rituximab in combination with rhIL-18 at doses of 1, 3, 10, 20, 30, and 100 μg/kg. Common side effects included chills, fever, headache, and nausea. Common laboratory abnormalities included transient, asymptomatic lymphopenia, hyperglycemia, anemia, hypoalbuminemia, and bilirubin and liver enzyme elevations. No dose-limiting toxicities were observed. Biologic effects of rhIL-18 included transient lymphopenia and increased expression of activation antigens on lymphocytes. Increases in serum concentrations of IFN-γ, GM-CSF, and chemokines were observed after dosing. Objective tumor responses were seen in 5 patients, including 2 complete and 3 partial responses. rhIL-18 can be given in biologically active doses by weekly infusions in combination with rituximab to patients with lymphoma. A maximum tolerated dose of rhIL-18 plus rituximab was not determined. Further studies of rhIL-18 and CD20 monoclonal antibodies in B-cell malignancies are warranted.

Original languageEnglish
Pages (from-to)331-341
Number of pages11
JournalJournal of Immunotherapy
Volume36
Issue number6
DOIs
StatePublished - Jul 2013

Fingerprint

Interleukin-18
Non-Hodgkin's Lymphoma
Lymphopenia
B-Cell Lymphoma
Lymphoma
Monoclonal Antibodies
Hypoalbuminemia
Chills
Maximum Tolerated Dose
Granulocyte-Macrophage Colony-Stimulating Factor
Bilirubin
Chemokines
Intravenous Infusions
Human Activities
Hyperglycemia
Nausea
Headache
Rituximab
Anemia
Neoplasms

Keywords

  • IFN-γ
  • IL-18
  • Lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-hodgkin Lymphoma. / Robertson, Michael; Kline, Justin; Struemper, Herbert; Koch, Kevin M.; Bauman, John W.; Gardner, Olivia S.; Murray, Sharon C.; Germaschewski, Fiona; Weisenbach, Jill; Jonak, Zdenka; Toso, John F.

In: Journal of Immunotherapy, Vol. 36, No. 6, 07.2013, p. 331-341.

Research output: Contribution to journalArticle

Robertson, M, Kline, J, Struemper, H, Koch, KM, Bauman, JW, Gardner, OS, Murray, SC, Germaschewski, F, Weisenbach, J, Jonak, Z & Toso, JF 2013, 'A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-hodgkin Lymphoma', Journal of Immunotherapy, vol. 36, no. 6, pp. 331-341. https://doi.org/10.1097/CJI.0b013e31829d7e2e
Robertson, Michael ; Kline, Justin ; Struemper, Herbert ; Koch, Kevin M. ; Bauman, John W. ; Gardner, Olivia S. ; Murray, Sharon C. ; Germaschewski, Fiona ; Weisenbach, Jill ; Jonak, Zdenka ; Toso, John F. / A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-hodgkin Lymphoma. In: Journal of Immunotherapy. 2013 ; Vol. 36, No. 6. pp. 331-341.
@article{f08e8445de884c7c9f9cbe3111e9fd20,
title = "A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-hodgkin Lymphoma",
abstract = "Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical models. Rituximab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. A phase I study of recombinant human (rh) IL-18 given with rituximab was performed in patients with CD20 lymphoma. Cohorts of 3-4 patients were given infusions of rituximab (375 mg/m) weekly for 4 weeks with escalating doses of rhIL-18 as a 2-hour intravenous infusion weekly for 12 consecutive weeks. Toxicities were graded using standard criteria. Blood samples were obtained for safety, pharmacokinetic, and pharmacodynamic studies. Nineteen patients with CD20 B-cell non-Hodgkin lymphoma were given rituximab in combination with rhIL-18 at doses of 1, 3, 10, 20, 30, and 100 μg/kg. Common side effects included chills, fever, headache, and nausea. Common laboratory abnormalities included transient, asymptomatic lymphopenia, hyperglycemia, anemia, hypoalbuminemia, and bilirubin and liver enzyme elevations. No dose-limiting toxicities were observed. Biologic effects of rhIL-18 included transient lymphopenia and increased expression of activation antigens on lymphocytes. Increases in serum concentrations of IFN-γ, GM-CSF, and chemokines were observed after dosing. Objective tumor responses were seen in 5 patients, including 2 complete and 3 partial responses. rhIL-18 can be given in biologically active doses by weekly infusions in combination with rituximab to patients with lymphoma. A maximum tolerated dose of rhIL-18 plus rituximab was not determined. Further studies of rhIL-18 and CD20 monoclonal antibodies in B-cell malignancies are warranted.",
keywords = "IFN-γ, IL-18, Lymphoma, Rituximab",
author = "Michael Robertson and Justin Kline and Herbert Struemper and Koch, {Kevin M.} and Bauman, {John W.} and Gardner, {Olivia S.} and Murray, {Sharon C.} and Fiona Germaschewski and Jill Weisenbach and Zdenka Jonak and Toso, {John F.}",
year = "2013",
month = "7",
doi = "10.1097/CJI.0b013e31829d7e2e",
language = "English",
volume = "36",
pages = "331--341",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-hodgkin Lymphoma

AU - Robertson, Michael

AU - Kline, Justin

AU - Struemper, Herbert

AU - Koch, Kevin M.

AU - Bauman, John W.

AU - Gardner, Olivia S.

AU - Murray, Sharon C.

AU - Germaschewski, Fiona

AU - Weisenbach, Jill

AU - Jonak, Zdenka

AU - Toso, John F.

PY - 2013/7

Y1 - 2013/7

N2 - Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical models. Rituximab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. A phase I study of recombinant human (rh) IL-18 given with rituximab was performed in patients with CD20 lymphoma. Cohorts of 3-4 patients were given infusions of rituximab (375 mg/m) weekly for 4 weeks with escalating doses of rhIL-18 as a 2-hour intravenous infusion weekly for 12 consecutive weeks. Toxicities were graded using standard criteria. Blood samples were obtained for safety, pharmacokinetic, and pharmacodynamic studies. Nineteen patients with CD20 B-cell non-Hodgkin lymphoma were given rituximab in combination with rhIL-18 at doses of 1, 3, 10, 20, 30, and 100 μg/kg. Common side effects included chills, fever, headache, and nausea. Common laboratory abnormalities included transient, asymptomatic lymphopenia, hyperglycemia, anemia, hypoalbuminemia, and bilirubin and liver enzyme elevations. No dose-limiting toxicities were observed. Biologic effects of rhIL-18 included transient lymphopenia and increased expression of activation antigens on lymphocytes. Increases in serum concentrations of IFN-γ, GM-CSF, and chemokines were observed after dosing. Objective tumor responses were seen in 5 patients, including 2 complete and 3 partial responses. rhIL-18 can be given in biologically active doses by weekly infusions in combination with rituximab to patients with lymphoma. A maximum tolerated dose of rhIL-18 plus rituximab was not determined. Further studies of rhIL-18 and CD20 monoclonal antibodies in B-cell malignancies are warranted.

AB - Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical models. Rituximab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. A phase I study of recombinant human (rh) IL-18 given with rituximab was performed in patients with CD20 lymphoma. Cohorts of 3-4 patients were given infusions of rituximab (375 mg/m) weekly for 4 weeks with escalating doses of rhIL-18 as a 2-hour intravenous infusion weekly for 12 consecutive weeks. Toxicities were graded using standard criteria. Blood samples were obtained for safety, pharmacokinetic, and pharmacodynamic studies. Nineteen patients with CD20 B-cell non-Hodgkin lymphoma were given rituximab in combination with rhIL-18 at doses of 1, 3, 10, 20, 30, and 100 μg/kg. Common side effects included chills, fever, headache, and nausea. Common laboratory abnormalities included transient, asymptomatic lymphopenia, hyperglycemia, anemia, hypoalbuminemia, and bilirubin and liver enzyme elevations. No dose-limiting toxicities were observed. Biologic effects of rhIL-18 included transient lymphopenia and increased expression of activation antigens on lymphocytes. Increases in serum concentrations of IFN-γ, GM-CSF, and chemokines were observed after dosing. Objective tumor responses were seen in 5 patients, including 2 complete and 3 partial responses. rhIL-18 can be given in biologically active doses by weekly infusions in combination with rituximab to patients with lymphoma. A maximum tolerated dose of rhIL-18 plus rituximab was not determined. Further studies of rhIL-18 and CD20 monoclonal antibodies in B-cell malignancies are warranted.

KW - IFN-γ

KW - IL-18

KW - Lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84880204487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880204487&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e31829d7e2e

DO - 10.1097/CJI.0b013e31829d7e2e

M3 - Article

C2 - 23799412

AN - SCOPUS:84880204487

VL - 36

SP - 331

EP - 341

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -